|
Volumn 37, Issue 5, 2011, Pages 418-421
|
Characteristics of and therapeutic options for contralateral axillary lymph node metastasis in breast cancer
|
Author keywords
Axillary dissection; Breast cancer; Contralateral axilla; Lymph nodes; Management
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
HORMONE RECEPTOR;
TAXANE DERIVATIVE;
TRASTUZUMAB;
ADULT;
ADVANCED CANCER;
AGED;
ARTICLE;
AXILLARY LYMPH NODE;
BREAST ADENOCARCINOMA;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER CONTROL;
CANCER HORMONE THERAPY;
CANCER INVASION;
CANCER MORTALITY;
CANCER STAGING;
CLINICAL ARTICLE;
CONTRALATERAL AXILLARY LYMPH NODE METASTASIS;
CONTROLLED STUDY;
FEMALE;
GENE OVEREXPRESSION;
HUMAN;
HUMAN TISSUE;
LYMPH NODE DISSECTION;
LYMPH NODE METASTASIS;
MEDICAL RECORD REVIEW;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT RESPONSE;
ADULT;
AGED;
AXILLA;
BREAST NEOPLASMS;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
LYMPH NODE EXCISION;
LYMPH NODES;
LYMPHATIC METASTASIS;
MIDDLE AGED;
NEOPLASM STAGING;
PALLIATIVE CARE;
RECEPTOR, ERBB-2;
RECEPTORS, ESTROGEN;
RECEPTORS, PROGESTERONE;
SALVAGE THERAPY;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
UP-REGULATION;
|
EID: 79954414403
PISSN: 07487983
EISSN: 15322157
Source Type: Journal
DOI: 10.1016/j.ejso.2011.01.024 Document Type: Article |
Times cited : (43)
|
References (9)
|